. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Nat Rev Clin Oncol. 2020 Jun 8;17(9):569–587. doi: 10.1038/s41571-020-0377-z

Table 3.

Targeted therapy outcomes by MET expression status

MET IHC	Drug	Disease	Trial (n)		IHC (−)	IHC (+)
Polyclonal antibody
AF276	rilotumumab + chemotherapy¹⁷³	prostate cancer	phase II (n=144)			+ low	+ high
				mPFS	-	3.6 mo	2.9 mo
				80% CI	-	(2.8–4.0)	(2.7–3.5)
Monoclonal antibodies
MET4	rilotumumab + chemotherapy¹⁷⁴	gastric/GEJ cancer	phase Ib/II (n=9 for Ib, n=121 for II)	mPFS	6.8 mo	4.4 mo
				mOS	11.1 mo	10.6 mo
				ORR	6/19 (32%)	20/40 (50%)
SP44	tivantinib¹⁹⁴	hepatocellular carcinoma	phase II (n=71)	mOS	3.8 mo	9.0 mo
	tivantinib + chemotherapy²⁰⁸	colorectal cancer	phase II (n=117)	mPFS	11 mo	7.9 mo
				mOS	NE	22.3 mo
				ORR	11/36 (31%)	24/54 (44%)
	onartuzumab + chemotherapy²⁰⁹	triple negative breast cancer	phase II (n=185)			+ low	+ high
	onartuzumab + chemotherapy²⁰⁹	triple negative breast cancer	phase II (n=185)	mPFS	7.3 mo	5.7 mo	10.3 mo
				mPFS	-	8.5 mo	4.4 mo
	onartuzumab + erlotinib²¹⁰	EGFR-mutant non-small cell lung cancer	phase II (n=61)	95% CI	-	(7.1–12.4)	(0.7-NE)
	onartuzumab + erlotinib²¹⁰	EGFR-mutant non-small cell lung cancer	phase II (n=61)	ORR		35/53 (66%)	7/8 (87%)
	onartuzumab + erlotinib¹⁷⁵	non-small cell lung cancer	phase II (n=137)			1+	2+	3+
				mPFS	1.4 mo	1.4 mo	4.1 mo	2.7 mo
				ORR	1/32 (3%)	3/35 (9%)
Unknown antibody	capmatinib	Non-small cell lung cancer	phase I (n=52)			1+	2+	3+
Unknown antibody	capmatinib	Non-small cell lung cancer	phase I (n=52)	ORR	-	-	2/12 (17%)	9/37 (24%)